Clinical trials: Malignant Melanomas
Melanoma
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma.
- Trial name
- NCT01153763
- Testing
- GSK2118436
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
- Trial name
- NCT01864538
- Testing
- TH-302
- Where
- 7 sites in United States, Canada
- Volunteers
- 11 people
- Sponsor
- ImmunoGenesis
Cancer., Melanoma.
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined with the adjuvant MPLA from B.
- Conditions
- Cancer., Melanoma., Ovarian Cancer., Lung Cancer.
- Trial name
- NCT01584115
- Testing
- NY-ESO-1 combined with MPLA, NY-ESO-1 combined with MPLA vaccine
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigação em Imunologia
Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Trial name
- NCT01950390
- Testing
- Bevacizumab, Ipilimumab
- Where
- 482 sites in United States
- Volunteers
- 169 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Fibrin Melanoma Axillary Node Study in Patients With Melanoma
Primary Objective: To determine whether the use of a fibrin sealant applied to axillary soft tissues following node dissection can result in earlier drain removal.
- Trial name
- NCT00504582
- Testing
- Fibrin Sealant
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00096382
- Testing
- aldesleukin, filgrastim, therapeutic tumor infiltrating lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
We hypothesize that combining anti-PD1 treatment with radiotherapy might result in improved clinical response rates and PFS compared to anti-PD1 treatment in monotherapy.
- Trial name
- NCT02821182
- Testing
- stereotactic body radiotherapy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Melanoma
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
This study is an open, single-center, multi-cohort phase Ib exploratory study, and 50 subjects are planned to be enrolled to observe the objective response rate of each subject.
- Trial name
- NCT05451407
- Testing
- TQB2618 injection, Toripalimab injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer, Colo-rectal Cancer
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the…
- Conditions
- Breast Cancer, Colo-rectal Cancer, Ovarian Cancer, Melanoma (Skin Cancer)
- Trial name
- PRO-ACTIVE (NCT07469709)
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Bladder Cancer, Kidney Cancer
Ex VIvo DEtermiNed Cancer Therapy
EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments.
- Conditions
- Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma
- Trial name
- EVIDENT (NCT05231655)
- Testing
- Functional drug screen
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
Melanoma of Skin
Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group.
- Trial name
- MELA_2025 (NCT06994208)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV…
- Trial name
- NCT00005633
- Testing
- OVA BiP peptide, gp209-2M antigen, recombinant 70-kD heat-shock protein
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cutaneous Melanoma, Anatomical Pathological Condition
Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.
Observational study to know the relevance of specific anatomical location of cutaneous melanoma on lower limbs.
- Trial name
- NCT04625491
- Testing
- Observational
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitario Virgen de la Arrixaca
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
This phase I trial studies how well tacrolimus, nivolumab, and ipilimumab work in treating kidney transplant recipients with cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT03816332
- Testing
- Ipilimumab, Nivolumab, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in…
- Trial name
- NCT02027935
- Testing
- Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Melanoma (Skin Cancer)
Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma
1. Primary Objective: To evaluate the safety of a low branched-chain amino acid diet (60% of the normal dietary BCAA content) combined with anti-PD-1 monoclonal antibody as neoadjuvant therapy in patients with stage III melanoma…
- Trial name
- NCT07586891
- Testing
- Low Branched-Chain Amino Acid Diet
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xijing Hospital
Melanoma (Skin)
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00109863
- Testing
- hu14.18-IL2 fusion protein
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.